“As we think about the QLEX adoption, we continue to think we are going to see 30% to 40% adopted as you get out to 2028, and we will drive that as high as we can.”

In context

“ally is extended out to May 2029, and the second one, a method of use patent goes out to November 2029. And so as we looked at this, initially, we were conservative in our assumptions and always based off the compound patent, always, though, with the intent that we would defend the entire patent estate. I think what has evolved over time is that this case law has emerged. Our confidence that we will be able to defend those additional two patents has grown. And thus, there is a potential that you are going to see protection actually make it through either May or November 2029. For planning purposes, we continue to assume 2028 because I think that is a conservative assumption. We will have to see where it goes. And I would also remind you that we do face the IRA as of the beginning of 2029. As we think about the QLEX adoption, we continue to think we are going to see 30% to 40% adopted as you get out to 2028, and we will drive that as high as we can. And as you know, we have priced this to drive for the adoption from KEYTRUDA IV to QLX. So that will continue. That strategy is underway. And frankly, whether it is '28 or '29 does not change the strategy we are following. Peter Dannenbaum: Great. Thanks, Alexandria. Next question, please. Operator: Thank you. Our next question comes from Evan Seigerman with BMO Capital Markets. You may ask your question. Evan Seigerman: Hi, guys. Thank you so much for taking my question. I want to touch on the HIV data that you were discussing. Can you just contextualize the importance of a dual regimen versus the standard of care of bictegravir Biktarvy, and kind of what is the feedback in more broadly unmet need for a dual regimen versus the standard of care triple? Thank you. Dean Y. Li: Yeah. So than”